Oesterreichische Post (OTC:OSTIY) Stock, Quote.Headers.trade-ideas

Oesterreichische Post AG is an Austrian postal, logistics, and mail service provider. The business activities include the provision of postal and parcel services, specialized logistics such as express mail delivery and value logistics, sales and telecommunications products and retail goods in the branch network, and provision of financial services. The service offering also encompasses fulfillment services, various online services such as e-letter and cross-media solutions, data and output management as well as document collection, digitalization, and processing. Its reportable segments include Mail, Parcel and Logistics, Retail and Bank, and Corporate.

OSTERREICHISCHE PST S/ADR by Osterreichische Post AG

Oesterreichische Post AG

Nyxoah Announces Commercial Launch of Genio&#xAE; Innovative Therapy in England First patients implanted with Genio at UCLH, London

News

NYXH

Nyxoah's Genio Neuromodulation Therapy Debuts In England With First Implants At UCLH Under NHS Coverage

While Gravity is divesting its water midstream assets, the company will retain ownership and operation of its power infrastructure assets, continuing its commitment to providing critical power generation offerings.
Clearlake and Gravity partnered in 2017 to pursue produced water midstream opportunities. Over the last several years, Gravity has focused on organically growing its water infrastructure business to support producers in the Midland and Williston basins, and its water business segment has quickly grown into one of the largest commercial operators of disposal wells in the Midland Basin. Gravity Water Midstream developed a system comprised of 200+ miles of permanent pipeline, 46 SWD facilities,&nbsp;and 14 fresh water facilities with over six million barrels of storage capacity, all of which form an extensive and interconnected network.

Reported Earlier, Delek Logistics Acquires Gravity Water Midstream's 200+ Mile Pipeline Network And Extensive Water Infrastructure In The Midland Basin

Equity Swap Settlement: cash settlement, within a maximum period of 12 months from December 13, 2024.
Maximum Exposure: up to 16,156,597 common shares, observing the limit established in CVM Resolution No. 77/22.
Conditions: the Equity Swap will allow the Company to receive the price variation related to its shares traded on the stock exchange plus any dividends distributed to the shares subject to the Equity Swap (active end) and pay CDI plus a fee (passive end), during the term of the agreement.
Purpose: need to mitigate fluctuations in the prices of shares issued by the Company, in view of future payments to be made by the Company within the scope of its long-term incentive plans.

Embraer-Empresa Brasileira De Aeronautica

Reported Earlier, Embraer Approves Equity Swap Agreements With Banco Itaú BBA To Stabilize Share Prices For Long-Term Incentive Plans

AGMH

Reported Earlier, AGM Group Holdings Acquires 2,000 Bitcoin Mining Machines, Secures Option For 30,000 More In Long-Term Crypto Strategy

<ul>
<li>Topline combination data for zelenectide pevedotin plus pembrolizumab in first-line metastatic urothelial cancer demonstrated a 60% overall response rate, in line with existing therapies</li>
<li>Dose selection and topline data from Phase 2/3 Duravelo-2 trial planned for 2H 2025</li>
<li>Heavily pretreated breast cancer and non-small cell lung cancer patients with NECTIN4 gene amplification and/or polysomy demonstrated an enhanced response to zelenectide pevedotin</li>
<li>Company to advance development strategy leveraging NECTIN4 gene amplification, with Phase 1/2 trials in breast cancer, lung cancer and multi-tumor planned for 2025</li>
<li>Bicycle Therapeutics to host conference call and webcast with management and oncology experts on Friday, Dec. 13, at 8 a.m. ET</li>
</ul>

BCYC

Reported Earlier, Bicycle Therapeutics Unveils Topline Data For Zelenectide Pevedotin In Combination And Monotherapy, Expanding Focus On NECTIN4 Cancers

Macro Economic Events

Econ #s

Economics

France Harmonised Index of Consumer Prices (MoM) For November 0.3% Vs. -0.1% Est.; 0.3% Prior

France Consumer Price Index (MoM) For November -0.1% Vs. 0.1% Est.; 0.3% Prior

ACOG

Reported Earlier, Alpha Cognition To Voluntarily Delist From Canadian Securities Exchange On December 17, 2024

US$10 million milestone payment to HUTCHMED follows first national reimbursement in Europe&nbsp;—
— Follows June 2024 European approval of FRUZAQLA&#xAE; (fruquintinib), the first novel oral targeted therapy in the EU for metastatic colorectal cancer regardless of biomarker status in over a decade&nbsp;—

Reported Earlier, HUTCHMED to Receive $10M Payment From Takeda As FRUZAQLA Achieves First National Reimbursement In Europe For Metastatic Colorectal Cance

SYH2039 targets solid tumors that have a mutation called MTAP deletion, which is estimated to be present in approximately 15 percent of all cancer types with the most common including glioblastoma, pancreatic cancer and non-small cell lung cancer.
"With one of the most dynamic solid tumor portfolios in the industry, we are continually assessing opportunities that align with our strategic focus and address significant unmet needs for patients. This MAT2A inhibitor is a valuable addition to our solid tumor pipeline, and we're eager to explore its potential, particularly in combination with our internally developed PRMT5 inhibitor, BGB-58067. Together, these assets hold promise for advancing treatment across a range of solid tumors," said Lai Wang, Ph.D., Global Head of R&amp;D at BeiGene.

BGNE

Reported Earlier, BeiGene Secures Global Licensing Agreement For Novel MAT2A Inhibitor SYH2039 To Target MTAP-Deleted Solid Tumors

Investigation Details: The Company has uncovered evidence suggesting that Yi Zhang, during his tenure in key executive roles, misappropriated corporate assets for personal gain and mismanaged the Company, resulting in significant financial losses over past several years, thereby seriously harming the interests of shareholders of the Company.
Corrective Actions: In response to these revelations, by March 2024, the Company took decisive action to remove Yi Zhang from all executive positions within the Company and its subsidiaries, in accordance with the Company's Memorandum and Articles of Association effective at that time and relevant laws. This action was necessary to mitigate the damage caused by Yi Zhang and his associates. Under the new leadership, the Company's financial and operational performance has seen a marked improvement. The Company has achieved smooth operations, secured second position in China's Rabies vaccine market and reaffirmed the full year financial guidance through Fiscal Year 2025 ended March 31, 2025.

Reported Earlier, LakeShore Biopharma Takes Decisive Action In Response To Criminal Allegations Against Former Chairman, Yi Zhang

Germany Trade Balance For October 13.4B Vs. 15.7B Est.; 17.0B Prior

U.K. Trade Balance Non-EU For October -7.28B Vs. -5.31B Prior

U.K. Trade Balance For October -18.97B Vs. -16.10B Est.; -16.32B Prior

U.K. Monthly Gross Domestic Product (GDP) 3M/3M Change For October 0.1% Vs. 0.2% Est.; 0.1% Prior

U.K. Manufacturing Production (MoM) For October -0.6% Vs. 0.2% Est.; -1.0% Prior

U.K. Industrial Production (MoM) For October -0.6% Vs. 0.3% Est.; -0.5% Prior

U.K. Gross Domestic Product (MoM) For October -0.1% Vs. 0.1% Est.; -0.1% Prior

With U.S. stock futures trading mixed this morning on Friday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) posted downbeat earnings and sales results for its third quarter. However, the company raised revenue guidance across the board based on current trends. The company expects fourth-quarter demand growth of 20% to 22%, and fourth-quarter revenue growth of 18% to 20%, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. RH shares jumped 17.7% to $448.70 in the after-hours trading session.</li>
<li>Wall Street expects 51Talk Online Education Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COE#NYSE">COE</a>) to report its unaudited financial results for the third quarter ended Sept. 30, before the opening bell. 51Talk Online Education shares fell 2.9% to $17.00 in after-hours trading.</li>
<li>Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) posted better-than-expected earnings for its fourth quarter. The company said it sees first-quarter revenue of approximately $14.6 billion, versus the $14.612 billion estimate. The company also issued adjusted EBITDA guidance of approximately 66 percent of projected revenue for the first quarter. Broadcom shares jumped 14.1% to $206.10 in after-hours trading.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Inovio Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) announced a proposed public offering. Inovio Pharmaceuticals shares dipped 21% to $2.9696 in the after-hours trading session.</li>
<li>Costco Wholesale Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) reported upbeat results for its first quarter on Thursday. The company reported first-quarter revenue of $62.15 billion, beating the consensus estimate of $62.08 billion. Costco shares fell 0.6% to close at $988.39 on Thursday.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42460676/jim-cramer-amd-ceo-lisa-su-built-an-amazing-company">Jim Cramer Says This CEO &#8216;Built An Amazing Company,&#8217; Recommends Buying Netflix</a></li>
</ul>
Photo courtesy: Shutterstock

Comments

Oesterreichische Post

Oesterreichische Post (OSTIY) Forecast

Oesterreichische Post (OTC:OSTIY) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga